# LAI Intelligence Weekly v3 (Test Bench) – 2025-12-12

Newsletter generated in fallback mode (Bedrock error).

## Top Signals – LAI Ecosystem

**Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-‘749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults**  
[Read more](https://www.medincell.com/wp-content/uploads/2025/12/MDC_Olanzapine-NDA-filing_09122025_EN_vf-2.pdf)

**DelSiTech Seeks an Experienced Quality Director**  
[Read more](https://www.delsitech.com/delsitech-seeks-an-experienced-quality-director/)

**DelSiTech is Hiring a Process Engineer**  
[Read more](https://www.delsitech.com/delsitech-is-hiring-a-process-engineer/)

**DelSiTech announces a leadership change. Carl-Åke Carlsson, CEO of DelSiTech, leaves the company and the Board nominates Martti Hedman as Interim CEO.**  
[Read more](https://www.delsitech.com/delsitech-announces-a-leadership-change-carl-ake-carlsson-ceo-of-delsitech-leaves-the-company-and-the-board-nominates-martti-hedman-as-interim-ceo/)

**Medincell Publishes its Consolidated Half-Year Financial Results (April 1st , 2025 – September 30, 2025)**  
[Read more](https://www.medincell.com/wp-content/uploads/2025/12/MDC_HY-Results-EN_09122025-1.pdf)

---

## Partnerships & Deals

---

## Regulatory Updates

---

## Clinical Updates

---

*Newsletter générée par Vectora Inbox – Powered by Amazon Bedrock*
